Workflow
121种药通过初审 国家医保局将首次制定商保创新药目录
Yang Shi Xin Wen·2025-08-13 06:09

Group 1 - The adjustment of the national medical insurance drug catalog for 2025 has been initiated, including the establishment of a commercial health insurance innovative drug catalog for the first time by the National Healthcare Security Administration [1] - The preliminary review of the first version of the commercial health insurance innovative drug catalog has been published, with 141 drug applications received, and 121 drug names passing the initial review [2] - The basic medical insurance system covers 1.326 billion people in 2024, maintaining a coverage rate of 95%, with total fund expenditure reaching 2.97 trillion yuan [3] Group 2 - The overall funding level of basic medical insurance is low, with an average funding of 1,070 yuan per person, of which about two-thirds comes from various levels of fiscal subsidies [5] - In 2024, the original insurance premium income of commercial health insurance in China reached 977.3 billion yuan, a year-on-year increase of 8.2%, approaching the total funding level of residents' medical insurance [7] - The establishment of the commercial health insurance innovative drug catalog is expected to enhance the integration of basic medical insurance and commercial health insurance funds, providing better economic support for innovative drug development [9]